These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2185935)

  • 41. Diabetic management by insulin infusion during major surgery.
    Meyer EJ; Lorenzi M; Bohannon NV; Amend W; Feduska NJ; Salvatierra O; Forsham PH
    Am J Surg; 1979 Mar; 137(3):323-7. PubMed ID: 373474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous versus intraperitoneal administration of insulin on post-prandial hyperglycaemia and glucose turnover in alloxan diabetic dogs.
    Rizza RA; Westland RE; Hall LD; Patton G; Haymond MW; Clemens AH; Gerich JE; Service FJ
    Diabetologia; 1982 Jul; 23(1):61-4. PubMed ID: 6749587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subcutaneous peritoneal access device for type I diabetic patients nonresponsive to subcutaneous insulin.
    Schade DS; Eaton RP; Warhol RM; Gregory JA; Doberneck RC
    Diabetes; 1982 May; 31(5 Pt 1):470-3. PubMed ID: 7152135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycemic regulation using a programmed insulin delivery device. III. Long-term studies on diabetic dogs.
    Goriya Y; Bahoric A; Marliss EB; Zinman B; Albisser AM
    Diabetes; 1979 Jun; 28(6):558-64. PubMed ID: 446916
    [No Abstract]   [Full Text] [Related]  

  • 45. Automated feedback control of subcutaneous glucose concentration in diabetic dogs.
    Rebrin K; Fischer U; von Woedtke T; Abel P; Brunstein E
    Diabetologia; 1989 Aug; 32(8):573-6. PubMed ID: 2673892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous infusions of sulfated insulin normalize plasma glucose levels in pancreatectomized dogs.
    Nomura M; Zinman B; Bahoric A; Marliss EB; Albisser AM
    Diabetes; 1983 Sep; 32(9):788-92. PubMed ID: 6354786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pumps for insulin infusion in the ambulatory treatment of diabetes mellitus].
    Mirouze J
    Presse Med; 1987 Oct; 16(32):1585-90. PubMed ID: 2958834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonaggregating insulin solutions for long-term glucose control in experimental and human diabetes.
    Albisser AM; Lougheed W; Perlman K; Bahoric A
    Diabetes; 1980 Mar; 29(3):241-3. PubMed ID: 6991326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of two intravenous insulin regimens among surgical patients with insulin-dependent diabetes mellitus.
    Simmons D; Morton K; Laughton SJ; Scott DJ
    Diabetes Educ; 1994; 20(5):422-7. PubMed ID: 7851255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Matched glucose responses to insulin administered subcutaneously and intravenously. Evidence for subcutaneous inactivation of insulin.
    Stevenson RW; Tsakok TI; Parsons JA
    Diabetologia; 1980 May; 18(5):423-6. PubMed ID: 7000596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An intraperitoneal insulin regimen for diabetics on continuous cyclic peritoneal dialysis.
    Aujla NS; Piraino B; Sorkin MI
    ASAIO Trans; 1990; 36(2):119-21. PubMed ID: 2187506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo effects of peroxovanadium compounds in BB rats.
    Yale JF; Vigeant C; Nardolillo C; Chu Q; Yu JZ; Shaver A; Posner BI
    Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):181-90. PubMed ID: 8927037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of different insulin administration modalities on vitamin D metabolism of insulin-dependent diabetic patients.
    Colette C; Monnier L; Arnal J; Selam JL; Mirouze J
    Adv Exp Med Biol; 1986; 208():501-8. PubMed ID: 3551545
    [No Abstract]   [Full Text] [Related]  

  • 54. A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes.
    Magisson J; Sassi A; Kobalyan A; Burcez CT; Bouaoun R; Vix M; Jeandidier N; Sigrist S
    J Control Release; 2020 Apr; 320():431-441. PubMed ID: 32014565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Future therapy of the insulin-dependent diabetic patient--the implantable insulin delivery system.
    Schade DS; Eaton RP; Carlson GA; Bair RE; Gaona JI; Love JT; Urenda RS; Spencer WJ
    Diabetes Care; 1981; 4(2):319-24. PubMed ID: 7011750
    [No Abstract]   [Full Text] [Related]  

  • 56. Insulin administration via a subcutaneous catheter. Effects on absorption.
    Käär ML; Mäenpää J; Knip M
    Diabetes Care; 1993 Oct; 16(10):1412-3. PubMed ID: 8269809
    [No Abstract]   [Full Text] [Related]  

  • 57. Possible effectiveness of plasmapheresis and immunosuppressive therapy in reversing subcutaneous insulin resistance: a case report.
    Vannini P; Forlani G; Giangiulio S; Santacroce G; Ciavarella A; Mustacchio A
    Diabete Metab; 1989; 15(2):98-101. PubMed ID: 2500372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycemic normalization using a preprogrammed insulin delivery device in unrestrained diabetic dogs.
    Albisser AM; Goriya Y; Bahoric A; Marliss EB
    Adv Exp Med Biol; 1979; 119():509-14. PubMed ID: 495299
    [No Abstract]   [Full Text] [Related]  

  • 59. Insulin administration via liposomes.
    Spangler RS
    Diabetes Care; 1990 Sep; 13(9):911-22. PubMed ID: 2226109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration.
    Micossi P; Cristallo M; Librenti MC; Petrella G; Galimberti G; Melandri M; Monti L; Spotti D; Scavini M; Di Carlo V
    Diabetes Care; 1986; 9(6):575-8. PubMed ID: 3542451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.